Last reviewed · How we verify
Cyclopentolate+tropicamide+phenylephrine
This combination of three anticholinergic and sympathomimetic agents dilates the pupil and paralyzes accommodation for ophthalmic examination.
This combination of three anticholinergic and sympathomimetic agents dilates the pupil and paralyzes accommodation for ophthalmic examination. Used for Mydriasis and cycloplegia for ophthalmic examination and diagnostic procedures.
At a glance
| Generic name | Cyclopentolate+tropicamide+phenylephrine |
|---|---|
| Also known as | Cyclogyl, Mydfrin, Mydriacyl |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Anticholinergic + sympathomimetic combination |
| Target | Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Cyclopentolate and tropicamide are anticholinergic agents that block muscarinic receptors in the eye, causing mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). Phenylephrine is an alpha-1 adrenergic agonist that enhances pupil dilation. Together, these agents facilitate comprehensive ophthalmic examination by maximizing pupil opening and temporarily eliminating the eye's focusing ability.
Approved indications
- Mydriasis and cycloplegia for ophthalmic examination and diagnostic procedures
Common side effects
- Transient stinging or irritation
- Blurred vision
- Photophobia
- Increased intraocular pressure
- Systemic anticholinergic effects (rare)
Key clinical trials
- Assessing Patient Comfort, Anxiety, and Satisfaction During CR Comparing Conventional Drops With ROC (NA)
- The Pathophysiology of Orthostatic Hypotension (PHASE1)
- Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study (PHASE4)
- Effect of Intracameral Injection of Mydriatic Plus Anaesthetic Combination on Corneal Endothelial Count in Phaco (PHASE3)
- A New More Efficient Cycloplegia Scheme (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: